Novavax said on Tuesday the World Health Organization’s (WHO) panel of experts had recommended a third dose of its vaccine, NVX-CoV2373, for immunocompromised persons. The WHO’s Strategic Advisory Group of Experts on Immunization, known as SAGE, issued a series of recommendations, including the use of the vaccine in persons with comorbidities, breastfeeding women, and those…
WHO Experts Recommend Third Dose of Novavax COVID Vaccine for People With Health Issues
European Union Authorizes COVID-19 Vaccine From US-Based Novavax
The European Union’s executive branch on Monday authorized Novavax’s COVID-19 vaccine, enabling its use in all 27 member-states. The European Commission previously cleared four COVID-19 vaccines, but Novavax’s, known as Nuvaxovid, is the first protein-based one. A European Medicines Agency panel earlier Monday said data from two clinical studies showed the vaccine is efficacious, safe, and of…
WHO Grants Emergency Approval to India’s Covovax to Boost Vaccination in Lower-Income Countries
The World Health Organization (WHO) on Friday has granted emergency approval for the India-made coronavirus vaccine NVX-CoV2373, also known as Covovax, to vaccinate more people in lower-income countries. “This listing aims to increase access particularly in lower-income countries, 41 of which have still not been able to vaccinate 10 percent of their populations, while 98…
WHO Listing to Novavax-Serum Institute’s COVID-19 Vaccine Clears Its Way for COVAX
The World Health Organization on Friday issued an emergency use listing to Serum Institute of India’s version of Novavax Inc.’s COVID-19 vaccine, paving the way for the two companies to ship their doses for the COVAX program. The EUL to the shot, Covovax, marks a significant milestone for Novavax as well, after the vaccine had…
US-based Company Developing Vaccine That Targets New COVID-19 Variant
An American biotechnology company is working on a version of its COVID-19 vaccine that specifically targets the newly identified Omicron variant. Maryland-based Novavax has already started developing the version, with plans to start testing it next month. The updated formulation revolves around a new spike protein, which triggers a response from the human immune system….
Novavax Developing Vaccine That Targets New COVID-19 Variant
Novavax Inc. said on Friday it had started working on a version of its COVID-19 vaccine to target the variant detected in South Africa and would have the shot ready for testing and manufacturing in the next few weeks. The company’s COVID-19 shot contains an actual version of the virus’ spike protein that cannot cause…
Novavax COVID-19 Vaccine Gets First Authorization; Expects More Within Weeks, CEO Says
Novavax Inc. expects regulators in India, the Philippines, and elsewhere to make a decision on its COVID-19 vaccine within “weeks,” its chief executive told Reuters, after the shot on Monday received its first emergency use authorization (EUA) from Indonesia. Novavax shares were up about 13 percent after the company also said it had filed an…
Japan to Purchase 150 Million Doses of Novavax COVID-19 Vaccine
Japan has agreed to purchase 150 million doses of the Takeda-produced Novavax COVID-19 vaccine, the drugmaker announced on Tuesday. The pharmaceutical company and Japan’s biggest drugmaker said in a statement that it is preparing to manufacture the Novavax COVID-19 vaccine domestically for distribution beginning early next year, pending approval from regulators. Takeda noted that the…
Denmark to Buy Novavax Vaccines as Part of EU Deal
COPENHAGEN, Denmark—Denmark said on Wednesday it would buy 280,000 doses of Novavax’s potential COVID-19 vaccine for a total price of 37 million Danish crowns ($5.84 million) or roughly $20.9 per dose as part of a European Union agreement with the U.S. company. The European Commission said earlier this month it had approved a supply contract…
Novavax Says Could Offer COVID-19 Vaccine Together With Flu Shot for Boosters
Novavax on Monday said that co-administering its protein-based COVID-19 vaccine with an approved flu shot may be a “viable immunization strategy” in the future, based on preliminary findings from a recent study. The American biotech firm made the announcement on Monday based on data from the first co-administration study of a COVID-19 vaccine candidate and…
US News
RSS Error: A feed could not be found at `https://www.theepochtimes.com/c-us/feed`; the status code is `200` and content-type is `text/html; charset=utf-8`